{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:38:20Z","timestamp":1792658300098,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"vor","delay-in-days":388,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jacc.2015.05.001","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T14:15:16Z","timestamp":1434377716000},"page":"2638-2651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"title":["Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?"],"prefix":"10.1016","volume":"65","author":[{"given":"Robert P.","family":"Giugliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2015.05.001_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMra1106700","article-title":"Proprotein convertases in health and disease","volume":"365","author":"Artenstein","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2015.05.001_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2015.05.001_bib4","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1086\/302370","article-title":"A\u00a0third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32","volume":"64","author":"Varret","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacc.2015.05.001_bib5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.ATV.20.4.1089","article-title":"Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred","volume":"20","author":"Hunt","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2015.05.001_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2015.05.001_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A\u00a0mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum Genet"},{"key":"10.1016\/j.jacc.2015.05.001_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in\u00a0Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2015.05.001_bib9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","article-title":"Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia","volume":"14","author":"Sun","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacc.2015.05.001_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2015.05.001_bib11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib12","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2015.05.001_bib13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2015.05.001_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2015.05.001_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"PCSK9 as a therapeutic target of dyslipidemia","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jacc.2015.05.001_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.05.001_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A\u00a0randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jacc.2015.05.001_bib18","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"issue":"Suppl 10","key":"10.1016\/j.jacc.2015.05.001_bib20","doi-asserted-by":"crossref","first-page":"A1577","DOI":"10.1016\/S0735-1097(15)61577-7","article-title":"Novel mechanism for the sustained durability of proprotein convertase subtilisin-kexin type 9 monoclonal antibody LY3015014","volume":"65","author":"Eacho","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib21","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.05.001_bib22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2013.09.048","volume":"63","author":"Desai","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib24","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 10","key":"10.1016\/j.jacc.2015.05.001_bib25","doi-asserted-by":"crossref","first-page":"A1591","DOI":"10.1016\/S0735-1097(15)61591-1","volume":"65","author":"Kastelein","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib26","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.05.001_bib28","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib30","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.05.001_bib31","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib32","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.05.001_bib33","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: A key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2015.05.001_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cjca.2013.03.004","article-title":"Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype","volume":"29","author":"Awan","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib35","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2015.05.001_bib36","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2015.05.001_bib39","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of\u00a0statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.05.001_bib40","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.05.001_bib41","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A\u00a052-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib42","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2015.05.001_bib44","first-page":"2108","article-title":"ODYSSEY ALTERNATIVE: Efficacy and safety of the\u00a0proprotein convertase subtilisin\/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm","volume":"130","author":"Moriarty","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.05.001_bib46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH\u00a0studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2015.05.001_bib47","unstructured":"Kastelein JP, Ginsburg HN, Langslet G, et\u00a0al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies. Paper presented at: European Society of\u00a0Cardiology Congress 2014; August 31, 2014; Barcelona, Spain."},{"key":"10.1016\/j.jacc.2015.05.001_bib48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of\u00a0longer-term administration of evolocumab (AMG\u00a0145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib49","unstructured":"Amgen. Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in high cardiovascUlar Risk Subjects (EBBINGHAUS). 2014. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02207634?term=NCT02207634&rank=1. Accessed April 30,\u00a02015."},{"key":"10.1016\/j.jacc.2015.05.001_bib50","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.05.001_bib51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2015.05.001_bib52","unstructured":"Amgen. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). 2015. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT01764633&Search=Search. Accessed April 30,\u00a02015."},{"key":"10.1016\/j.jacc.2015.05.001_bib53","unstructured":"Pfizer. The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). 2015. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT01975376&Search=Search. Accessed April 30,\u00a02015."},{"key":"10.1016\/j.jacc.2015.05.001_bib54","unstructured":"Pfizer. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). 2015. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT01975389&Search=Search. Accessed April 30,\u00a02015."},{"key":"10.1016\/j.jacc.2015.05.001_bib55","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.05.001_bib56","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.05.001_bib57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from\u00a0the JUPITER trial (Justification for the Use of\u00a0Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib59","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib61","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI117292","article-title":"The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate","volume":"93","author":"Rader","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2015.05.001_bib62","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib63","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/01.cir.0000441139.02102.80","article-title":"Heart disease and stroke statistics\u20142014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib64","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.amjcard.2014.10.021","article-title":"Frequency of high-risk patients not receiving high-potency statin (from a large managed care database)","volume":"115","author":"Rodriguez","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib65","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.05.001_bib67","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61730-X","article-title":"Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.05.001_bib69","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1161\/CIRCULATIONAHA.111.047480","article-title":"Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987\u20132008","volume":"125","author":"Rosamond","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1377\/hlthaff.2014.1123","article-title":"Medicare is scrutinizing evidence more tightly for national coverage determinations","volume":"34","author":"Chambers","year":"2015","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jacc.2015.05.001_bib71","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ecl.2014.08.008","article-title":"New therapies for reducing low-density lipoprotein cholesterol","volume":"43","author":"Stein","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jacc.2015.05.001_bib72","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib73","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.05.001_bib74","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2013primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"issue":"Suppl 12","key":"10.1016\/j.jacc.2015.05.001_bib75","doi-asserted-by":"crossref","first-page":"A1374","DOI":"10.1016\/S0735-1097(14)61374-7","volume":"63","author":"Ballantyne","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib76","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.05.001_bib77","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.05.001_bib78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"International J Cardiol"},{"issue":"Suppl 10","key":"10.1016\/j.jacc.2015.05.001_bib79","doi-asserted-by":"crossref","first-page":"A1369","DOI":"10.1016\/S0735-1097(15)61369-9","article-title":"Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: results from the phase III YUKAWA 2 study","volume":"65","author":"Kiyosue","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.05.001_bib80","unstructured":"Stroes ESG, Guyton J, Farnier M, et\u00a0al. Efficacy and safety of different dosing regimens of alirocumab (starting doses of 75 mg every two weeks and 150 mg every four weeks) versus placebo in patients with hyperchoelsterolemia not treated using statins: The ODYSSEY CHOICE I and II studies. Paper presented at: American College of Cardiology 64th Annual Scientific Sessions and Expo 2015; March 14, 2015; San Diego, CA."}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109715021865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109715021865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T15:53:48Z","timestamp":1537545228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109715021865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":80,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0735109715021865"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2015.05.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725579871.793516687","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2015.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}